NCT07403968RecruitingPhase 2
A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease
An Open-Label, Single-Arm, Phase 2a Trial to Evaluate the Safety, Tolerability, PK, and Mechanism of Action of Zasocitinib (TAK-279) in Participants With Active Crohn's Disease
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
Crohn's disease (CD) is a serious, long-term condition that can cause swelling (inflammation) and painful ulcers anywhere in the gut. This study will investigate whether zasocitinib can improve CD biology at the cellular and molecular level in adults. The main aims of this study are to better understand zasocitinib's mechanism of action in CD and evaluate how safe this treatment is. The participants will be treated with zasocitinib for 3 months (12 weeks) and will need to undergo a test where a doctor uses a thin, flexible tube with a tiny camera to look inside the large bowel (colon) and the end of the small bowel (ileum); this test is called ileocolonoscopy. During the study, participants will visit the study clinic several times.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 4 Feb 2026
- Start date
- 13 Aug 2026
- Primary completion date
- 30 Mar 2028
- Lead sponsor
- Takeda
- Diseases
- Crohn's disease
- NCT number
- NCT07403968
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 20
- From 13 Aug 2026 to the primary completion date, 30 Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Cannot have complications of CD which may require surgery.
- Cannot have current abscesses or abscesses that have been treated within 6 weeks before study start.
- Cannot have had any surgery inside the belly (intraabdominal) within 3 months before study start.
Other illness
- Cannot have another condition that causes swelling (inflammation) in the bowel.
- Cannot have had infections up to 2 months (8 weeks) before study start.
Other
- Cannot have had a removal of parts of the bowel within half a year (6 months) before study start.
- Cannot have or had a J-pouch.
- Cannot have given blood or plasma within 1 month (30 days) before study start.
- Cannot tolerate having blood taken with a needle from a vein (venipuncture).
- Additional entry criteria will be discussed with the study doctor.
Who the study is looking for
- Men and women aged 18 to 75 years can participate in the study.
- Must have been diagnosed with Crohn's disease (CD) at least 1 month (30 days) before study start.
- Must have received other treatments for CD earlier but no longer tolerate these treatments or the treatment no longer helps.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oxford Experimental Medicine Clinical Research Facility Coordinator of this site? Confirm its status | Oxford | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.